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multiorgan failure. No unexpected OT was noted. Fifty-four of the
72 patients (75%) received VOR until day 100 without interrup-
tion. The reasons for VOR discontinuation were increased LFTs
in 11 patients, prolonged QTc in 2, and suspected resistant IFI in
2. The LFT increases were transient. The median total bilirubin,
alkaline phosphatase, and AST values were 1.3 mg/dL, 134 U/L,
and 34 U/L, respectively. Eight patients developed total biliru-
bin  6 mg/dL, and 3 had VOD. Four patients restarted VOR
following improved LFTs. No signiﬁcant cardiac toxicity was
noted, despite a QTc of  500 msec in 10 patients. The mean
increase in QTc after starting VOR was 34 msec (n  36). The
mean peak creatinine level was 1.5 mg/dL. Four patients required
HD. Engraftment did not appear to be adversely affected, with
means of 14 days to ANC  0.5/L and of 20 days to platelets 
50 103/L. VOR did uniformly increase serum tacrolimus levels,
necessitating a 60% reduction in tacrolimus dosing. Conclusions:
VOR appears safe and effective as prophylaxis for AT. Tacrolimus
levels must be closely monitored. A randomized trial comparing
VOR to FLU in AT is warranted.
262
ANTIFUNGAL PROPHYLAXIS WITH VORICONAZOLE IN ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
Magalhaes-Silverman, M., Carter, T., Hohl, R., Shamsuddin, H.,
Gingrich, R. University of Iowa, Iowa City, IA.
Background: Invasive fungal infection (IFI) remains a major
cause of morbidity and mortality in recipients of allogeneic hema-
topoietic stem cell transplantation (HSCT). In many transplanta-
tion centers, Aspergillus has been the leading cause of death from
fungal infections. Voriconazole is a triazole with broad-spectrum
antifungal activity against several molds, including Aspergillus. In
our institution, voriconazole was instituted as antifungal prophy-
laxis in July 2002. Before the institution of voriconazole, invasive
aspergillosis (IA) was the most commom fungal infection in our
allogeneic HSCT population, with 3 years of surveillance revealing
a cumulative incidence of proven or probable IA of 12%. Meth-
ods: From July 2002 to March 2004, 40 adult patients undergoing
allogeneic HSCT received oral voriconazole 200 mg every 12
hours from initiation of the preparative regimen until at least
posttransplantation day 100. After day 100, voriconazole was
continued in patients requiring corticosteroids for therapy of
GVHD. Intravenous voriconazole was allowed in patients not able
to take oral medications. All these patients were at high risk for
Aspergillus infection. Diagnoses included myeloid malignancies in
23 patients, lymphoid malignancies in 16, and renal cell cancer in
1. Median patient age was 47 years. Some 75% of the patients had
advanced disease, and 50% received an unrelated donor transplant.
T-cell depletion was achieved using either OKT3 or Campath-1H
in 75% of the patients. GVHD requiring high-dose corticosteroids
occurred in 50% of the patients. Results: Voriconazole had to be
discontinued in 1 patient due to hallucinations; this patient devel-
oped and died from IA. Three cases of candidemia caused by
Candida glabrata were diagnosed (all 3 cases caused by voricon-
azole-resistant organisms). Disseminated zygomycosis was identi-
ﬁed and caused the death of 2 patients at days 25 and 196 after
transplantation. Conclusions: In this high-risk patient population,
only 1 case of IA was diagnosed. This compares favorably with
historical results: However, 2 cases of disseminated zygomycosis
were diagnosed. Our experience raises concern regarding the
changing epidemiology of IFI as practices using prophylactic an-
tifungal agents evolve.
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PHARMACOKINETICS OF HIGH-DOSE WEEKLY AMBISOME (LIPOSO-
MAL AMPHOTERICIN B) ANTIFUNGAL PROPHYLAXIS IN PEDIATRIC
BONE MARROW TRANSPLANTATION (BMT) PATIENTS
Mehta, P.A., Vinks, A.A., Filipovich, A.H., Vaughn, G.A.,
Fearing, D.N., Sper, C., Davies, S.M. Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH.
Background: Disseminated fungal infection is a major cause of
morbidity and mortality in children undergoing BMT. Prophylac-
tic oral triazoles are limited by poor absorption, interindividual
variation in metabolism, and hepatic toxicity. Ambisome is shown
to produce higher plasma and tissue concentrations and has a
better safety proﬁle than the parent drug amphotericin B; however,
it requires frequent intravenous administration. Both animal (mu-
rine models for Candida/Histoplasma) and human (adult) data show
measurable plasma and tissue levels at 7 days after a single dose
(2–20 mg/kg) of Ambisome. We hypothesized that weekly high-
dose Ambisome will provide adequate fungal prophylaxis for im-
munocompromised children. This dosing schedule will improve
compliance and broaden the applicability of Ambisome to a larger
patient population.Methods: A total of 14 children (M/F ratio 2:1,
age 10 years [mean age, 3.3 years]) with various hematologic
conditions, metabolic disorders, and immunodeﬁciency syndromes
at risk for invasive fungal infection received once-a-week intrave-
nous Ambisome prophylaxis at the dose of 10 mg/kg given over 2
hours. Blood samples were drawn for phrmacokinetic (PK) mea-
surements around the ﬁrst and the fourth weekly doses. PK analysis
of single-dose and steady-state data was conducted using standard
noncompartmental methods. Individual plasma trough concentra-
tions were determined by visual inspection of the plasma concen-
tration time proﬁles. The area under the plasma concentration
versus time curve (AUC0-) was determined using the log-linear
trapezoidal rule. Total body clearance (CL), volume of distribution
(Vz), and terminal half-life (T1⁄2) were calculated using standard
equations. Results: Ambisome was well tolerated at this dosage.
Half-life measured in this pediatric population appears to be
shorter than reported in adults (45 hours vs 152 hours). Volume of
distribution and clearance were higher compared to adult reports
and correlated positively with body weight (r2  0.62 for Vz; r2 
0.28 for Cl). Plasma levels at 7 days (Cmin) were not signiﬁcantly
different after the ﬁrst and fourth doses, suggesting no accumula-
tion over the course of therapy. Conclusions: Our data show
measurable plasma levels present 7 days after the dose. Adult
studies show tissue concentrations  10-fold higher than plasma
concentrations, suggesting that once-weekly dosing, as described
in this study, likely provides useful protection against fungal infec-
tion.
Table 1. Pharmacokinetic Parameters After Weekly Ambisome (10
mg/kg)
Parameters (Unit)
After Single
Dose (n  12)
After Multiple
Doses (n  9)
T1⁄2 (h) 45.44 (15.43) 58.94 (26.42)
Day 7 plasma trough
(Cmin; mg/L) 0.23 (0.14) 0.51 (0.46)
AUC0-INF (hr  mg/L) 157.51 (71.71) 230.08 (132.67)
Vz (L/kg) 4.29 (1.01) 4.97 (2.96)
Cl (L/hr/kg) 0.0742 (0.0341) 0.0669 (0.0442)
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EVALUATION OF ANTIBIOTIC CYCLING AND PROPHYLAXIS FOR NEU-
TROPENIC FEVER WITHIN A BLOOD AND MARROW TRANSPLANTA-
TION UNIT
Craig, M.1, Cumpston, A.1, Shields, R.2, Devetten, M.3, Sarwari, A.1,
Ericson, S.1 1West Virginia University, Morgantown, WV; 2St. Jo-
seph’s/ Candler Health System, Savannah, GA; 3University of Ne-
braska, Omaha, NE.
Background: Bacterial resistance to antibiotics is an increasing
problem and associated with signiﬁcant morbidity and mortality.
Patients undergoing HSC transplantation and treatment for he-
matologic malignancy are at high risk of infection. We evaluated
whether rotating the empiric antibiotics for patients who develop
neutropenic fever in this setting resulted in decreased emergence
of resistant organisms and decreased vancomycin use. Methods:
Within the BMTU, all patients with neutropenic fever were em-
pirically treated with piperacillin plus gentamicin (intermittent
dosing) from January 1999 to February 2002. From March 2002
through June 2004, 3 antibiotic regimens were cycled every 8
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